Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pregnancy-specific beta-1-glycoprotein 2 (PSG2) is a secreted, glycosylated protein produced by placental trophoblasts and released into the maternal circulation, mainly during pregnancy[1][2][3][5]. It is a member of the pregnancy-specific glycoprotein (PSG) family, a subgroup within the carcinoembryonic antigen (CEA) gene family, itself part of the immunoglobulin superfamily[2][3][4][5]. PSG2, like other PSGs, features an N-terminal Ig variable-like domain and multiple immunoglobulin constant-like A/B domains. Most PSGs, including PSG2, contain an Arg-Gly-Asp (RGD) motif that mediates interactions with integrins and may function as a cell adhesion recognition signal[1][2][3][5]. The PSGs play key roles in the maternal-fetal interface, believed to modulate the maternal immune system and support successful pregnancy[4], although the specific functions of PSG2 remain less clearly defined in comparison to the family as a whole[2][4]. Family-wide, abnormal levels of PSGs are associated with pregnancy complications, but PSG2 is not a recognized therapeutic target and has no established drug interactions[4]. Special notes: - PSG2 is not considered a direct therapeutic target (e.g., as a receptor, enzyme, transporter) but rather a biomarker/component of a broader glycoprotein family important in pregnancy[1][2][3][4][5]. - There is confusion in the literature and databases between PSG2, PSG1, and generic "CEA," but PSG2 refers specifically to "pregnancy-specific beta-1-glycoprotein 2" as encoded by the PSG2 gene (NCBI Gene ID: 5670)[3]. - Some sources list "PSG1" and "CEA" as aliases, but these are more appropriately applied to the family or other members, contributing to ambiguity; the canonical identity is "Pregnancy-specific beta-1-glycoprotein 2 (PSG2)."
Not therapeutically targeted; any biological effects inferred from family properties (adhesion, immune modulation)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pregnancy-specific beta-1-glycoprotein 2 (PSG2).